Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MBX
MBX BIOSCIENCES, INC. COMMON STOCK
NASDAQ
$63.00
▼ DOWN 5.11% (-3.39)

KEY STATISTICS

Market Cap$3.00 B
52w High$72.64
52w Low$9.63
Dividend Yield—
Frequency—
P/E-26.14
Volume307.64K
Shares Out.47.60M

COMPANY

LEADERSHIP

Steve Hoerter
CHIEF EXECUTIVE
Steve Hoerter

COMPENSATION 2026

Salary$625,000
Stock Awards$0
Incentive Plan Pay$359,375
All Other Comp.$8,400
Total$2,990,867

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 13, 2024
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
63

PRICE TARGET

Target High$90.00
Target Low$56.00
Target Median$88.00
Target Consensus$80.50

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

PRICE

$63.00 ▼ DOWN 5.11% (−$3.39)
$63.00$64.00$65.00$66.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM63.00

About MBX Biosciences, Inc. Common Stock

https://mbxbio.com ↗

MBX Biosciences is a clinical-stage biopharma developing precision peptide therapies for endocrine and metabolic disorders, including treatments for hypoparathyroidism, post-bariatric hypoglycemia, and obesity.

INDUSTRY

Biotechnology

A PRODUCT MBX BIOSCIENCES, INC. COMMON STOCK IS KNOWN FOR

Canvuparatide (MBX 2109)
Canvuparatide (MBX 2109)

An investigational, long-acting hormone therapy for chronic hypoparathyroidism, currently preparing for Phase 3 trials, with potential to be a best-in-class, once-weekly treatment.

COMPETITORS

COMPETITOR
ASND COMPARE
AZN COMPARE
BBIO COMPARE
ENTX COMPARE
PTCT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
123
LISTED HERE
23
RANKED BY POSITION SIZE
VTI
0.00% · 1.1M
XSU.TO
0.07% · 790.3K
XPH
3.04% · 269.1K
FESM
0.15% · 149.2K
SCHA
0.04% · 127.4K
DFAS
0.03% · 75.6K
PTH
1.41% · 59.8K
SBIO
1.53% · 58.6K
AVSC
0.12% · 56.4K
OZEM
3.09% · 31.7K
XRSU.L
0.06% · 28.4K
NUSC
0.10% · 22.8K
RSSL
0.06% · 14.8K
BBC
1.12% · 8.8K
GSSC
0.05% · 8.1K
PILL
2.05% · 7.6K
HRTS
0.56% · 5.0K
ETLZ.DE
0.05% · 1.8K
BIB
0.11% · 1.7K
TILT
0.00% · 1.3K
TNXT
0.15% · 415
PCSG
0.48% · 195
RESM
0.09% · 85

INSTITUTIONAL OWNERSHIP

SHARES OWNED
79.67%
HOLDERS
188
TOP 12 OF 188 · RANKED BY POSITION SIZE
Frazier Life Sciences Management, L.P.
6.7M sh · $198.56M
Wellington Management Group Llp
4.8M sh · $84.41M
Orbimed Advisors LLC
4.0M sh · $70.05M
Nea Management Company, LLC
3.6M sh · $107.89M
Deep Track Capital, LP
3.2M sh · $102.5M
Blackrock, Inc.
2.9M sh · $87.8M
Fmr LLC
2.9M sh · $87.66M
Nvp Associates, LLC
2.1M sh · $63.77M
Ecor1 Capital, LLC
2.1M sh · $66.98M
Kynam Capital Management, LP
2.0M sh · $35M
Vanguard Group Inc
1.8M sh · $57.33M
Polar Capital Holdings Plc
1.6M sh · $48.42M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Azoulay Salomon
Sale · 370 shares
2026-08-04
★
OFFICER: CHIEF FINANCIAL OFFICER
Smither John W
Purchase · 130.0K shares
2026-08-03
★
OFFICER: CHIEF FINANCIAL OFFICER
Smither John W
Purchase · 28.0K shares
2026-08-03
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Hoerter Steven L.
Purchase · 331.0K shares
2026-08-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 2
OVERWEIGHT 1
MARKET OUTPERFORM 1
7 GRADES IN THE LAST 12 MONTHS
Truist Securities BUY Mizuho OUTPERFORM Barclays OVERWEIGHT Citizens MARKET OUTPERFORM Guggenheim BUY Stifel BUY Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
ERAS$18.03COMPARE
IOVA$8.01COMPARE
AVBP$30.17COMPARE
REPL$15.50COMPARE
MGTX$13.82COMPARE
MLTX$14.99COMPARE
VSTM$7.22COMPARE
RGNX$9.66COMPARE